The Quantellect read.As of Nov 19, 2026, 7 active firms cover Kiniksa Pharmaceuticals Ltd: 7 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets span $71.00 to $107.00, a moderate spread. The average target of $91.29 sits 4% below the current $95.01. The rating mix has stayed broadly stable, with Buy-side ratings easing from 8 to 7 over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.44 next quarter toward $2.18 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS7 active firms
Buy
Strong Buy00%
Buy7100%
Neutral00%
Sell00%
Strong Sell00%
Based on 7 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$91.29
-3.9% downside
Average target across 7 active firms as of Nov 19, 2026 vs $95.01 current
Highest Target$107.00
Average Target$91.29
Lowest Target$71.00
Detailed analyst forecasts for KNSA
Showing 1–7 of 7 named analysts shown · 7 active firms in the rating projection
As of Nov 19, 2026, 7 of 7 active firms rate KNSA a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
KNSA EPS & revenue forecast
EPS · NEXT QUARTER
$0.44
Range $0.29 – $0.55 · 4 analysts · +63% YoY
Next period, 4 analysts expect Kiniksa Pharmaceuticals Ltd to earn $0.44 a share (range $0.29 – $0.55), versus $0.27 a year earlier. Full-year consensus is $1.50, growing to $2.18 the year after.
REVENUE · NEXT QUARTER
$313.8M
Range $310.0M – $320.9M · 4 analysts · +46% YoY
Revenue is expected to reach $313.8M (range $310.0M – $320.9M), +46.4% year-over-year. Full-year consensus is $1.0B, rising to $1.3B next year.
Top analysts covering Kiniksa Pharmaceuticals Ltd
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on KNSA.
#1
David Nierengarten
Wedbush · Rank #24
Buy
$99.00+4.2% to target
Overall win rate
48%
+ Follow
#2
Paul Choi
Goldman Sachs · Rank #110
Buy
$90.00-5.3% to target
Overall win rate
52%
+ Follow
#3
Roger Song
Jefferies · Rank #122
Buy
$71.00-25.3% to target
Overall win rate
43%
+ Follow
#4
Anupam Rama
JP Morgan · Rank #171
Buy
$107.00+12.6% to target
Overall win rate
48%
+ Follow
#5
EN
Edward Nash
Canaccord Genuity · Rank #270
Buy
$98.00+3.1% to target
Overall win rate
44%
+ Follow
KNSA stock forecast FAQ
What is KNSA's average 12-month price target?+
The 7 active firms with a live target average $91.29 for Kiniksa Pharmaceuticals Ltd over the next 12 months, ranging from a $107.00 high to a $71.00 low, as of Nov 19, 2026.
Is KNSA stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 7 active firms as of Nov 19, 2026, 7 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for KNSA?+
The Street-high target is $107.00 (JP Morgan), and the Street-low is $71.00 (Jefferies). The average of all 7 active-firm targets is $91.29.
How many active Wall Street firms cover KNSA?+
7 active firms have a recognized rating on Kiniksa Pharmaceuticals Ltd as of Nov 19, 2026, and 7 active firms carry a live 12-month price target.
Who is the most accurate analyst covering KNSA?+
Among analysts who currently cover KNSA, David Nierengarten of Wedbush has the strongest overall Quantellect track record (Rank #24). Their current call is Buy with a $99.00 target.
What is Kiniksa Pharmaceuticals Ltd's projected EPS for next quarter?+
The consensus estimate is $0.44 per share (range $0.29 – $0.55) across 4 analysts. Full-year EPS is projected at $1.50, rising to $2.18 the following year.
How much revenue is Kiniksa Pharmaceuticals Ltd expected to report next quarter?+
Consensus revenue is $313.8M (range $310.0M – $320.9M). Full-year revenue is projected at $1.0B, growing to $1.3B next year.
Have analysts been upgrading or downgrading KNSA lately?+
As of Nov 19, 2026, 7 of 7 active firms rate KNSA a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their KNSA calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.